EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis

Joachim Almquist iD, Yen Lin Chia iD, Raj Tummala iD, Lynn Bertagnolli iD, David Jayne iD, Weifeng Tang iD, Catharina Lindholm iD

Clinical Pharmacology & Therapeutics · 2026-08 · 120 (2) · 429-439

DOI: 10.1002/cpt.70307 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 22.05.2026. Verfasst von Joachim Almquist und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Lupus Nephritis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In patients with systemic lupus erythematosus (SLE), increased type I interferon signaling is associated with increased disease activity across organs, including in the kidney, which can cause lupus nephritis (LN). Anifrolumab, which abrogates type I interferon signaling, is an approved treatment for moderate to severe SLE. In a phase 2 trial in patients with LN (TULIP‐LN; NCT02547922), promising clinical benefit was observed with an intensified regimen (IR) of intravenous anifrolumab (3× 900 mg Q4W, 300 mg thereafter) compared with the approved SLE dose (basic regimen [BR], 300 mg Q4W). Anifrolumab clearance was greater with higher levels of proteinuria; however, the quantitative relationship between proteinuria and anifrolumab exposure was not fully characterized. Here, we describe a mathematical model of time‐varying anifrolumab pharmacokinetics, 24‐hour urine protein–creatinine ratio (UPCR24), and investigational product discontinuation in patients with LN. The model evaluated both TULIP‐LN anifrolumab dosing regimens (IR and BR) and revealed a temporal association between clearance and proteinuria in patients with LN, with each mg/mg UPCR reduction resulting in a 21% decrease in linear anifrolumab clearance. Our model indicated that an intensified regimen including 6 initial anifrolumab 900 mg doses provided adequate exposure and rapid UPCR24 reduction. Higher anifrolumab exposure and reduced UPCR24 were each associated with decreased risk of treatment discontinuation. These model results guided the selection of an optimized, longer intensified anifrolumab dosing regimen (6× 900 mg Q4W, 300 mg thereafter) for the ongoing phase 3 IRIS trial (NCT05138133).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLupus NephritisAdultFemaleHumansMaleDose-Response Relationship, DrugModels, BiologicalProteinuriaTreatment Outcome

Substanzen

anifrolumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, California, USA.
  • Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Department of Medicine, University of Cambridge, Cambridge, UK.
  • Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

ORCID-Profile: Joachim Almquist, Yen Lin Chia, Raj Tummala, Lynn Bertagnolli, David Jayne, Weifeng Tang, Catharina Lindholm

Zitieren

APA

Almquist, J., Chia, Y. L., Tummala, R., Bertagnolli, L., Jayne, D., Tang, W., & Lindholm, C. (2026). Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis. Clinical Pharmacology & Therapeutics, 120(2), 429-439. https://doi.org/10.1002/cpt.70307

Vancouver

Almquist J, Chia YL, Tummala R, Bertagnolli L, Jayne D, Tang W, et al. Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis. Clinical Pharmacology & Therapeutics. 2026;120(2):429-439. doi:10.1002/cpt.70307

BibTeX
@article{Almquist2026,
  author = {Almquist, Joachim and Chia, Yen Lin and Tummala, Raj and Bertagnolli, Lynn and Jayne, David and Tang, Weifeng and Lindholm, Catharina},
  title = {Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {2},
  pages = {429--439},
  doi = {10.1002/cpt.70307}
}
Kostenlos starten →